Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
-
4001
50 µM resveratrol is toxic to C<sub>2</sub>C<sub>12</sub> myotubes.
Published 2013“…<p>(A) Exposure to 50 µM resveratrol (RSV) for 24 h is toxic to C<sub>2</sub>C<sub>12</sub> myotubes resulting in a decrease in viable cells and (B) a decrease in ATP content. …”
-
4002
-
4003
-
4004
-
4005
-
4006
Svaldi et al.’s “High Load” and “Low Load” groups from a soccer season (High Load percentiles: 25th = 4515 g, 50th = 5615 g, 75th = 12313 g; Low Load percentiles: 25th = 2425 g, 50...
Published 2020“…<p>Post-season adjustments to the High Load group: 19.7% reduction from decreasing inflation pressure from 1.10 bar (16 psi) to 0.55 bar (8 psi), 7.1% reduction from downsizing a size 5, 0.55 bar (8 psi) ball to size 4.5, 0.55 bar (8 psi) ball (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0240162#pone.0240162.t003" target="_blank">Table 3</a>), and a 20% reduction in number of hits based on average PLA per hit (Adjusted High Load percentiles: 25th = 2463 g, 50th = 3063 g, 75th = 6718 g).…”
-
4007
-
4008
-
4009
-
4010
-
4011
-
4012
-
4013
-
4014
Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
4015
Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
4016
Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
4017
-
4018
-
4019
-
4020